JNJ-4528 Continues to Show Strong, Durable Responses in Trial
Janssen’s investigational CAR T-cell therapy for…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreWhile myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreJanssen’s investigational CAR T-cell therapy for…
A pivotal Phase 3 study investigating melflufen (melphalan flufenamide)…
The U.K.’s National Institute for Health and Care…
Karyopharm Therapeutics is asking that Xpovio (selinexor)…
The European Commission (EC) has approved a new…
The European Commission (EC) has approved Sanofi‘s…